Bioequivalence Study of Two Olaparib Tablets in Patients With Cancers

Inclusion Criteria:

* Had BMI 18.0 kg/m\^2, and weight ≥ 50 kg for male, or ≥ 45 kg for female
* Patients who were on olaparib treatment, had epithelial ovarian, fallopian tube, or primary peritoneal cancer, or were eligible for olaparib treatment judged investigators
* Had ECOG performance status 0-1
* Had life expectancy \>12 weeks
* Had Adequate organ function or clinically irrelevant abnormal result
* Agreed to use adequate contraception from 14 days before treatment initiation to 6 months after last dose

Exclusion Criteria:

* Allergic to any component of study drugs
* Had central nervous system metastases (stable and asymptomatic metastases were acceptable)
* Had other malignancy within 5 years
* Had disease affecting swallow or absorption
* Received major surgery within 1 month before study drug administration
* Had major disease
* Had continuous grade 3-4 adverse event
* Had drug abuse
* Had (suspected) pneumonitis
* Participated in other clinical trial of drug or device within 1 month
* Lost or donated blood \> 200 mL or received blood transfusion within 1 month
* With average alcohol consumption \> 14 units/week or cigarette consumption \> 20/day within 1 month
* Positive for human immunodeficiency virus, hepatitis B, C, or syphilis test
* Received strong or moderate CYP3A inducer or inhibitor within 3 half-lives of the drug
* Consumed grape fruit juice, or other food or beverage containing caffeine or xanthine
* For female, pregnant or breastfeeding